Lumida
/NEO
⌘K
Neogenomics Inc

Neogenomics Inc

NEO
$17.32USD-1.65%-0.29 today

MARKET CAP

2.2B

P/E (TTM)

FWD P/E

DAY RANGE

$17 – $18

52W RANGE

$7
$20

AI Summary

Stalk
TrimMedium

NEO exhibits a classic Blow-Off Top at recent highs, signaling exhaustion after a parabolic rally. While the long-term trend remains intact above the rising 200-day SMA, medium-term directional asymmetry has turned bearish due to the unsustained spike and heavy volume exhaustion. In the short term, price is pulling back into the 9-day EMA without a clear breakdown, indicating that selling should be deferred until rallies into structural resistance near the prior spike high.

  • Q2 revenue of $201.7M rose 11% YoY, beating guidance
  • NGS revenue surged 26% YoY, now ~33% of clinical revenue
  • Non-clinical pharma revenue fell 26% YoY, pressuring mix
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$484.3M$509.7M$591.6M$660.6M$727.3M
YoY %+9.0%+5.2%+16.1%+11.6%+10.1%
P / Sales8.5x2.2x3.4x3.2x2.1x
EV / Sales9.4x3.2x4.1x3.7x2.6x
Gross Profit, Adj.$187.1M$187.9M$244.6M$290.1M$314.3M
YoY %+0.6%+0.4%+30.2%+18.6%+8.3%
Margin %38.6%36.9%41.3%43.9%43.2%
EV / Gross Profit24.3x8.6x9.8x8.5x6.0x
EBITDA, Adj.$-65.4M$-83.7M$-24.1M$-12.9M$-20.3M
YoY %-401.0%-27.9%+71.2%+46.4%-57.4%
Margin %-13.5%-16.4%-4.1%-2.0%-2.8%
EV / EBITDA-69.4x-19.2x-99.7x-190.4x-92.1x
EBIT$-118.8M$-157.6M$-107.7M$-92.1M$-115.9M
YoY %-748.7%-32.7%+31.6%+14.5%-25.8%
Margin %-24.5%-30.9%-18.2%-13.9%-15.9%
EV / EBIT-38.2x-10.2x-22.3x-26.7x-16.1x
Net Income$-8.3M$-144.3M$-88.0M$-78.7M$-108.0M
YoY %-300.1%-1628.2%+39.0%+10.5%-37.2%
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (GAAP)-$0.07-$1.16-$0.70-$0.62-$0.84
YoY %-275.0%-1557.1%+39.7%+11.4%-35.5%